This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This Phase 1 study confirmed the safety of spartalizumab given at a dose of up to 10 mg/kg every 2 weeks in Japanese patients with cancers.
This page is a summary of: Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies, Cancer Science, December 2020, Wiley,
DOI: 10.1111/cas.14678.
You can read the full text:
The following have contributed to this page
Health Psychology and Behavioral Medicine
The aim of this study was to investigate the relationships between self-reported physical activity (PA), exercise self-efficacy and body satisfaction in a sample of older adults with Type 2 diabet...
Pharmacogenomics and Personalized Medicine
There are people who suffer from adverse drug reactions. Some may experience muscle pain, others feel sleepy, others taking one drug will expericen no improvement. These reactions can be explained ...
International Immunopharmacology
Type 1 diabetes and LADA are autoimmune diseases with loss of immune tolerance and reduced function and number of beta cells. DPP-inhibitors and vitamin D3 have effects about immune system and bet...
